可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] 朱妙章,钱学贤,臧益民,等. 缺血/再灌注损伤的机制与防治原则[J]. 心脏杂志,2001,13(6):566-571.
[2]李小鹰. 冠脉微循环病变的临床特点与防治[J]. 微循环学杂志 2004,14(3):9-12.
[3] 陈小林,查道刚,谢志斌,等. 再灌注治疗后心肌无再流现象的危险因素[J]. 中国循环杂志, 2002, 17(3):173-176.
[4] 陈在嘉. 再灌注治疗应当重视心肌微循环的灌注[J]. 中国循环杂志, 2002,17(3):163-164.
[5] 臧伟进,赵正航,于小红,等. 腺苷的心脏作用及其机制[J]. 心脏杂志,2002,14(5):438-439.
[6] Fugit MD,Rubal BJ,Donovan DJ. Effects of intracoronary nicardipine,diltiazen and verapamll on coronary blood flow[J]. J Invasive Cardiol,2000,12:80-85.
[7] Taniyama Y,Ito H,Morishita R,et al. Potential of microvascuiar reperfusion with adjunctive pharmacological intervention[J]. Drugs,2001,61(4):437-441.
[8]Dalby M,Montalescot G. Transfer for primary angioplasty;who and how?[J]. Heart,2002,88:570-572.
[9] Montalescot G. Defining standards of care for facilitated and direct percutaneous coronary intervention[J]. Clin Cardial,2002,25(11 suppl 1):127-132.
[10] Cator WJ,Ohman EM.Facilitated PCI for acute MI:PCI with lysis and platelet inhibition[J]. Curr Interv Cardial Rep,2001,3:321-329.
[11] Herrmann HC, Kelly MP,Ellis SG.Facilitated PCI:rationale and design of the FINESSE Trial[J]. J Invasive Cardial,2001,13(suppl A):10A-15A.